Xbrane Biopharma AB (publ)
STO: XBRANE.ST0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Stockholm Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Martin Amark
- Employees
- 65
- Headquarters
- Solna, Sweden
- IPO year
- 2016
- Market cap
- SEK 116.9M
- Website
- https://www.xbrane.com
Loading XBRANE…
Loading profile data…Frequently asked questions about XBRANE
What does Xbrane Biopharma AB (publ) (XBRANE.ST) do?
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its...
Where does XBRANE.ST trade?
Xbrane Biopharma AB (publ) (XBRANE.ST) trades on the Stockholm Stock Exchange.
What sector is XBRANE.ST in?
Xbrane Biopharma AB (publ) (XBRANE.ST) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Xbrane Biopharma AB (publ)?
Martin Amark is the chief executive officer of Xbrane Biopharma AB (publ) (XBRANE.ST).
Where is Xbrane Biopharma AB (publ) headquartered?
Xbrane Biopharma AB (publ) is headquartered in Sweden.
Does XBRANE.ST pay a dividend?
Xbrane Biopharma AB (publ) (XBRANE.ST) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did XBRANE.ST go public?
Xbrane Biopharma AB (publ) (XBRANE.ST) completed its initial public offering in 2016.